Samsung Biologics Acquires Swiss PolyPeptide Group for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Samsung Biologics is making a blockbuster acquisition of PolyPeptide Group AG, a Swiss peptide contract development and manufacturing…